The Viral Vector and Plasmid DNA Manufacturing Market is estimated to reach USD 1902.7 Million by 2028 from USD 601.8 Million in 2021, growing at a Compound Annual Growth Rate (CAGR) of 16.1% between2022-2028. Viral vectors and plasmid DNA are the products of gene therapy used for the treatment of several diseases like Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis. Gene therapies and other therapies that require genetic modification include the introduction of therapeutic DNA/genes into a patient's body or cell by using vectors. Viral vectors and plasmid DNA are known to reduce the cost of treatment and help in decreasing repeated administration of medications.
Virus vector vaccines are among the COVID-19 vaccine candidates under clinical studies. Many of them have either gotten or are nearing completion of approval. Johnson & Johnson published positive effectiveness and safety findings from their Phase 3 ENSEMBLE clinical trial for COVID-19 utilizing its AdVac vaccination technology in January 2021. Its single-dose COVID-19 vaccine, which is now being developed by Janssen Pharmaceutical Companies, satisfied all preconditions and objectives. The AdVac viral vector technology has the potential to give the body a powerful and long-lasting humoral and cellular immune response. The Oxford-AstraZeneca COVID-19 vaccine is another viral vector-based vaccination that has obtained many approvals. COVID-19 viral vector vaccines are being developed across the world utilizing non-replicating viral vectors. Given the delicacy of pandemic, this is sure to drive the market for Viral Vector and Plasmid DNA Manufacturing. Viral vector design and production are vital for overall product quality, safety, and efficiency in patients due to issues such as replication competence, vector integration, and vector shedding. Significant progress has been made in the development of innovative viral vectors, and some researchers are working on replacing harmful genes with therapeutic DNA. Non-pathogenic, replication-defective, and human-friendly viral vectors are now frequently employed in gene therapy clinical studies.
The Global Viral Vector and Plasmid DNA Manufacturing Market is divided according to product type into plasmid DNA, viral vector, and non-viral vector. Based on application, the market is segmented into cancer, genetic condition, infectious illness, and others. While geographically, the market consists of regions of North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America. The Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market is currently expanding rapidly. Companies in the region are developing innovative viral vector product techniques.
Catalent and Delphi Genetics, for example, agreed into a formal and definitive agreement in February 2021 to purchase 100 percent of Delphi Genetics' shares. Catalent's pDNA development and manufacturing services were introduced at its Rockville, Maryland plant. Many businesses are also expanding their manufacturing plants. For example, Genopis Inc. stated in January 2020 that it will establish a contract manufacturing firm for plasmid DNA manufacture in the United States with its South Korean partner Helixmith.
Key players of the Global Viral Vector and Plasmid DNA Manufacturing Market include Fujifilm Diosynth Biotechnologies (US), SIRION Biotech (Germany), Thermo Fisher Scientific (US), Merck KGaA Inc. (US), Cognate BioServices Inc. (Cobra Biologics) (US) are the major companies operating in Global Viral Vector and Plasmid DNA Manufacturing Market.